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Abstract
Introduction: Data from clinical studies on the long-term efficacy and safety of anti-tumor necrosis factor (TNF)-a
therapy in patients with ankylosing spondylitis (AS) are scarce. This is the first report on continuous treatment with
the TNFa fusion protein etanercept over seven years (y).
Methods: Overall, 26 patients with active AS were initially treated with etanercept 2 × 25 mg s.c./week with no
concomitant disease modifying anti-rheumatic drugs (DMARDs) or steroids. The clinical response was assessed by
standardized parameters. The primary outcome was the proportion of patients in the Spondyloarthritis International
Society (ASAS) partial remission at seven years. AS disease activity scores (ASDAS) for status and improvement were
compared to conventional outcome measures.
Results: Overall, 21/26 patients (81%) completed two years of treatment and 16/26 patients (62%) completed
seven years. In the completer analysis, 31% patients were in ASAS partial remission at seven years, while 44%
patients showed an ASDAS inactive disease status. Mean Bath AS activity index (BASDAI) scores, which were
elevated at baseline (6.3 ± 0.9), showed constant improvement and remained low: 3.1 ± 2.5 at two years and 2.5 ±
2.2 at seven years, while ASDAS also improved (3.9 ± 0.7 at baseline, 1.8 ± 0.9 at two years, 1.6 ± 0.8 at seven
years), all P <0.001. From the 10 dropouts, only 5 patients discontinued treatment due to adverse events. Patients
who completed the study had lower baseline Bath AS function index (BASFI) scores vs. patients who discontinued.
No other clinical parameter at baseline could predict any long-term outcome.
Conclusions: This study confirms the clinical efficacy and safety of etanercept in patients with active AS over
seven years of continuous treatment. After seven years, more than half of the initially treated patients remained on
anti-TNF therapy, and one-third were in partial remission.
Trial Registration: ClinicalTrials.gov: NCT01289743
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Introduction
Ankylosing spondylitis (AS), the prototype and the most
severe form of the spondyloarthritides (SpA), is a frequent
chronic inflammatory rheumatic disease with a prevalence
of 0.1% to 1.1% [1]. AS affects young patients and fre-
quently starts in the third decade of life, being initially
characterized by inflammation of the axial skeleton but
also by new bone formation in later stages. The socioeco-
nomic burden of AS patients is substantial since absence
from work and work disability are increased by three-fold
[2-4].
Therapeutic options for patients suffering from AS
have been limited over the last decades. There is no evi-
dence that disease modifying anti-rheumatic drugs
(DMARDs) work in axial manifestations of AS with the
exception of sulfasalazine, which has some efficacy in
AS patients with peripheral symptoms [5,6]. Non-steroi-
dal anti-inflammatory drugs (NSAIDs) are considered
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first-line therapy in AS, while for patients with no
response to NSAIDs treatment with anti-tumor necrosis
factor (TNF)-a is the only alternative [7].
The efficacy of the recombinant 75 kD-TNF receptor
IgG1 fusion protein etanercept has been demonstrated in
clinical studies with patients with active AS [8-12], show-
ing a significant decrease of disease activity already after
the first two weeks [8-10] of treatment. In parallel, a signif-
icant decrease of inflammatory lesions in the sacroiliac
joints and the spine as detected by magnetic resonance
imaging (MRI) was detected as early as six weeks after the
start of treatment [13,14].
After our first report from a placebo-controlled study of
over three months with successful etanercept treatment in
patients with initially active AS [8], and also successful and
safe re-administration after treatment discontinuation (due
to lack of medication at that time), we reported the clinical
experience of the efficacy and safety of continuous therapy
with etanercept over two years [15]. Similar data were
reported also from other authors after two [16] or five
years [17] of follow-up. This is the first report on clinical
efficacy and safety of continuous treatment with etaner-
cept over seven years in patients with established AS.
Materials and methods
Patients and study protocol
The local ethics committees of the universities of Berlin
and Muenster approved the initial study [8] and the pre-
sent extension, and patients gave written informed consent
before participation. After the placebo-controlled phase of
this trial [8] and treatment discontinuation, all patients
(n = 26) entered the open-label phase of the study [18] if
they had experienced a clinical relapse defined as a Bath
AS disease activity index (BASDAI, [19]) ≥4 and a score of
≥4 on a 0 to 10 numeric rating scale (NRS) for spinal pain.
All patients fulfilled the 1984 modified New York criteria
[20] and were treated continuously with etanercept (2 ×
25 mg s.c./week) for a total of seven years. Patients were
allowed to continue on the same or a lower dose of
NSAIDs during the study, as compared to their treatment
before inclusion in the study.
Assessment of clinical response
Disease status was assessed by using internationally
accepted parameters for disease activity (ASDAS [21],
BASDAI), function (BASFI, [22]) and metrology (BASMI,
[23]). Furthermore, patient’s (PatGA) and physician’s
(PhysGA) global assessments were also assessed on a 0 to
10 NRS. Laboratory parameters, such as C-reactive pro-
tein (CRP, mg/l), were measured by conventional means.
The Short Form (SF)-36 questionnaire [24] was used to
assess the health-related quality of life for both the physi-
cal and mental component using the algorithm of the
Medical Outcome Trust [25].
Treatment efficacy was assessed by using the core set
of criteria for symptomatic improvement in AS as sug-
gested by the Assessment of SpondyloArthritis interna-
tional Society (ASAS) [26], with a 20%, a 40% response,
and an improvement in five out of the six criteria.
These outcomes have been already described in detail
[26,27]. Furthermore, ASAS partial remission (PR) was
defined as a score ≤2 (on a NRS of 0 to 10) in each of
the four ASAS 20% domains [26] and was compared
with the definition of inactive disease status as defined
in the ASDAS [21]. A status of low disease activity was
defined as described in the ASDAS cut-offs [21] and
was compared to a BASDAI ≤3, in accordance with a
recent report by our group [28] and from previous data
of the same study [15].
The primary endpoint of the study was the percentage
of patients being in ASAS partial remission at Year 7.
Similar data were collected for the ASDAS inactive dis-
ease status and these results were compared for each
year of the study. Secondary endpoints were the propor-
tion of patients who met the ASAS 40% criteria, ‘5-out-
of-6’ criteria as well as the mean improvement of the
BASDAI, ASDAS, CRP, BASFI, BASMI and SF-36 after
seven years.
Statistical analysis
The analysis of the data was done as completer analysis.
The Mann-Whitney-U test was used for comparison
between subgroups of patients (for example, completers
vs. dropouts) and the Wilcoxon test was used for com-
parison of variables between different time points.
Fisher´s exact test was used for the comparison of cate-




Out of the 26 patients who were randomized into the
original study [8], 21 patients (81%) completed the two-
year and 16 patients (62%) completed the seven-year
treatment period (14 males and 2 females, mean age at
baseline 36.3 ± 7.5 years; range 23 to 52 years). The
baseline disease characteristics of these patients did not
differ from those who discontinued the study. Interest-
ingly, in the BASFI status, the completers had a lower
BASFI at baseline (5.3 ± 1.9) as compared to drop-outs
(6.8 ± 1.6), but also this difference did not reach signifi-
cance (P = 0.054). Table 1 shows the baseline character-
istics of these two subgroups.
Clinical efficacy of etanercept during the seven years of
continuous treatment
Overall, 5/16 patients (31.3%) were in ASAS partial
remission status (Figure 1), while 7/16 patients (43.8%)
showed an ASDAS inactive disease status by the end of
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Year 7 (Figure 2). Mean ASDAS, BASDAI, BASFI and
BASMI scores showed a rapid improvement, which
remained stable over the entire study period (Figure 3).
There was no change in mean values at Year 7 of the
study as compared to the last report of the same
patients after two years. The mean ASDAS decreased
from 3.9 ± 0.7 units at baseline to 1.8 ± 0.9 units at two
years and to 1.6 ± 0.8 units at seven years (both P <
0.001 as compared to baseline), while the mean BASDAI
decreased from 6.3 ± 0.9 at baseline to 2.5 ± 2.2 at
seven years. A BASDAI of <3 units was achieved by
8/16 patients (50%) at Year 2 and by 11/16 patients
(68.8%) at Year 7, while ASDAS moderate disease activ-
ity was achieved by 11/16 patients (68.8%) at both Year
2 and Year 7 (including those patients who were in
ASDAS inactive disease, as described above).
The clinical improvement based on the ASAS criteria
but also on the BASDAI-50% improvement indicated
sustained benefit of treatment from the first year of the
study and onwards up to Year 7 in any of the applied
measures (Figure 1). ASAS40 response was achieved in
9/16 patients (56.3%) at Year 2 and in 11/16 patients
(68.8%) at Year 7. An ASDAS major clinical improve-
ment was achieved in 9/16 patients (56.3%) at Year 2
and in 10/16 patients (62.5%) at Year 7 (Figure 4).
Analysis of patients who did not show low disease activity
status after seven years despite continuous treatment
with etanercept
The analysis of the 4/16 patients (25%) who did not reach
a BASDAI of <3 or ASDAS moderate disease activity at
the end of Year 7 showed that 3 out of 4 of these patients
had been in ASDAS high disease activity or ASDAS mod-
erate disease at the end of each study year.
The BASDAI values for each of these four patients at
the end of Year 7 ranged between 3.6 and 8.1, the ASDAS
values ranged between 2.1 and 3.0 and the BASFI values
ranged between 4.4 and 7.8. Furthermore, their CRP
values improved during treatment and, although being
increased prior to treatment, were normalized during the
study period (mean: 4.2 mg/l, range 2.0 to 6.0 mg/l at the
end of Year 7).
Changes in health-related quality of life (SF-36) and global
assessments over seven years of etanercept treatment
Both components of the SF-36 improved significantly
during treatment and remained at high levels until the
end of the study. The PCS increased from 30.8 ± 6.8
points at baseline to 43.1 ± 7.7 points at Year 7, while the
MCS increased from 40.6 ± 11.5 points at baseline to





age (years) 36.3 ± 7.5 38.4 ± 11.0
Male gender (n, %) 14 (87.5%) 6 (60%)
disease duration (years) 13 ± 7.7 15 ± 10.8
BASDAI (0 to 10) 6.3 ± 0.9 7.0 ± 1.4
BASFI (0 to 10) 5.3 ± 1.9 6.8 ± 1.6
BASMI (0 to 10) 3.9 ± 2.2 3.7 ± 1.3
CRP (mg/l) 20.8 ± 17.7 19.3 ± 16.7
ASDAS units 3.9 ± 0.7 4.3 ± 0.9
HLA positive (n patients, %) 13 (81.3%) 10 (100%)
Baseline disease characteristics of the patients who completed Year 7 of the
study (n = 16) and of those who discontinued during the seven years of
treatment with etanercept. None of these parameters was significantly
different when the two investigated groups were compared (all P > 0.05)
Figure 1 Treatment outcome for each study year. Response data for the 16 patients reaching Year 7. Treatment outcome according to
established clinical parameters for each year of the study. ASAS20, ASAS 20% response, ASAS40, ASAS 40% response, ASAS 5/6, ASAS 5/6
response, BASDAI50, BASDAI 50% response, ASAS PR, ASAS partial remission. Shown are the response data for the 16 patients reaching Year 7 at
different time points. ASAS, SpondyloArthritis international Society; BASDAI, Bath Ankylosing Spondylitis Activity Index
Baraliakos et al. Arthritis Research & Therapy 2013, 15:R67
http://arthritis-research.com/content/15/3/R67
Page 3 of 9
46.7 ± 11.2 points at Year 7 (P < 0.001 for the change in
both components).
Correlations between ASDAS and other assessments of
disease activity or treatment outcome
Cross tabulations were generated in order to evaluate the
concordance of the categorical assessments based on
ASDAS compared to the outcomes based on other mea-
sures (ASAS40, ASAS partial remission, low BASDAI sta-
tus of <3 units).
The analysis of ASAS40 vs. ASDAS improvement
(major, clinically important, or no improvement) showed
that only one patient at years 2, 3 and 4 experienced an
ASDAS major clinical improvement, but was regarded as
an ASAS40 non-responder (Table 2).
Some more patients with discordant assessments were
observed in the comparison of ASDAS status (inactive,
moderate, high or very high disease activity) vs. ASAS par-
tial remission, since the numbers of patients with ASDAS
inactive disease in the absence of ASAS partial remission
ranged between 1 and 4 at study years 2 to 7, while another
patient had achieved ASAS partial remission in spite of
high disease activity based on ASDAS at Year 7 (Table 3).
Low BASDAI (<3 units) despite high ASDAS disease
activity was noted in only very few patients, while one
patient had no low BASDAI but was in ASDAS inactive dis-
ease at Year 2.
Analysis of safety and reasons for treatment
discontinuation over seven years
Episodes of recurrent uveitis were found in 7/16 patients
(44%) during the entire study period, 5 of which devel-
oped uveitis during treatment with etanercept without a
Figure 2 Completer analysis for ASDAS status over seven years. Completer analysis (n = 16) for the disease activity status as defined by the
ASDAS over the entire study period of seven years. Numbers in the columns indicate the number of patients achieving the outcome. ASDAS,
Ankylosing Spondylitis Disease Activity Score
Figure 3 Course of disease related clinical parameters: ASDAS, BASDAI, BASFI, BASMI. Completer analysis. Course of disease related clinical
parameters: ASDAS, Ankylosing spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index, BASFI, Bath
Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index. Completer analysis of the 16 patients who reached
Year 7 of the study.
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previous history of uveitis. In three of those patients,
uveitis was noticed only once while the other two
patients had 2 and 11 episodes of uveitis, respectively,
during the seven years of the study. In the remaining
two patients, who both had already reported uveitis at
least once prior to inclusion in the study, there were
one and six episodes of uveitis over seven years of
treatment.
Overall, there were no differences in baseline status
between those patients who completed the seventh
year of the study and those who dropped out before
Year 7 (data not shown). Ten patients of the initial 26
patients dropped out due to different reasons: the most
common reason for discontinuation was moving to
another place or lack of efficacy (both n = 2), while
one patient discontinued because she wanted to
become pregnant. The other reasons for discontinua-
tion were heart discomfort, development of Crohn´s
disease, reactivation of Crohn´s disease, lung carci-
noma and death (probably due to heart attack), respec-
tively. The two patients who discontinued due to lack
of efficacy did not differ in their baseline characteristics
from the others who discontinued due to an adverse
event (data not shown).
Figure 4 ASDAS Change status for completers over seven years. Change status of the ASDAS for the 16 completers over the entire study period of
seven years. Numbers within the columns indicate the number of patients achieving the outcome. ASDAS, Ankylosing spondylitis Disease Activity Score.
Table 2 Cross tabulation of ASDAS change vs. ASAS40 response
ASDAS change

































































Numbers in the boxes represent the numbers of patients achieving the different combinations of responses.
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Discussion
This is the first report on seven years of treatment with
the receptor fusion protein etanercept in patients with
ankylosing spondylitis. Our data show that continuous
treatment with etanercept over such a long time period
was efficacious and safe.
All patients in this study were participants of the first
placebo-controlled phase of the study and had already dis-
continued etanercept but had to resume therapy after
about four months due to clinical relapse and a high level
of disease activity. However, their clinical response after
etanercept re-administration was similar to their status
prior to discontinuation. These data have been reported
elsewhere [8,28] and suggest that continuous treatment
with TNF-blockers is recommended for the treatment of
patients with active AS, as shown also with other anti-
TNF compounds [28]. However, when needed, treatment
discontinuation and then the resumption of therapy are
possible without loss of clinical efficacy in the long term.
Importantly, the clinical efficacy of etanercept on disease
activity, function and mobility was sustained over seven
years. Both patient-oriented (BASDAI) and objective
(CRP) measures for disease activity had already shown sig-
nificant improvement at week 2 of the study [8], continued
to improve during the first six months and remained on
similar low levels over the entire study period, indicating
no loss in the efficacy of etanercept after seven years.
Furthermore, low BASDAI levels (a BASDAI of <3 units)
and also ASDAS levels of <2.1 units were reported by the
majority of the patients, indicating the sustainable effect of
etanercept in the long-term treatment of active AS. Finally,
the sustained improvements in the clinical composite
measures or CRP were accompanied by stable improve-
ments in the global assessment of the disease by patients
and physicians, as well as in the mental and physical com-
ponent scores of the SF-36.
Interestingly, not only parameters for disease activity but
also function (BASFI) and metrology (BASMI) showed a
similar course with sustained low levels over the seven
years of the study. This is important information as com-
pared to a very recent report on long-term anti-TNF treat-
ment over eight years, where we had observed a slight
increase of BASFI levels in comparison to previous years,
a finding which also contributed to a slight decrease in the
proportion of patients achieving partial remission at the
end of that study. Although the number of patients in the
current study is too limited to draw further conclusions, it
seems that, overall, BASFI increases seem not to be a con-
stant phenomenon in AS patients treated with anti-TNF
for longer time periods. Furthermore, the reported restric-
tion of mobility as measured by the BASMI remained at
low levels over the seven years of etanercept treatment,
supporting the efficacy of this compound in the long-term,
especially with the known natural course of the disease
and the expected continuous worsening of function and
mobility in AS patients not treated with anti-TNF [29,30].
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Overall, we found no correlation between the baseline
clinical status of the patients and the response to or main-
tenance of treatment after seven years with a slight excep-
tion of the baseline BASFI status, which just reached
statistical significance. In previous studies [31-33], younger
age, lower BASFI, raised CRP or higher BASDAI were
identified as predictors of a major (BASDAI50) clinical
response in patients with active AS treated with TNF
blockers. The results of the present study may be
explained by the relatively low number of completers after
seven years.
Another important result of this study is the comparison
between established methods of disease activity status
(BASDAI) or response to treatment (ASAS outcomes) and
the recently introduced ASDAS method. Although
ASDAS has been tested retrospectively in AS patients with
a short-term follow-up, our study is, to our knowledge,
the first report of ASDAS being tested as an outcome
measure for a long-term follow-up. Both the BASDAI sta-
tus but also ASAS outcomes were in good agreement with
the ASDAS on status and on changing scores for disease
activity during the long-term treatment with anti-TNF.
The very few cases of discordance seemed to appear rather
sporadically in single cases, thus indicating a high degree
of concordance of the assessments made with the ASDAS
compared to the outcomes based on the traditional disease
activity measures. It is worth mentioning that in some
patients this discordance was seen in ASDAS inactive dis-
ease compared to ASAS partial remission. This is an inter-
esting result with respect to the long-term outcome aspect
described herein. We believe that the reason for this
observation has to do with impaired function that often
occurs in the long-term course of the disease, even under
effective anti-TNF blocker treatment. Since function is
part of the ASAS partial remission criteria, this fact is
most probably responsible for failure in reaching ASAS
partial remission as a long-term outcome. It remains to be
seen, in future long-term analyses and larger cohorts,
whether reaching a low ASDAS early in the course of
treatment can also be applied as a predictive measurement
for long-term outcomes in AS patients treated with anti-
TNF, something which has already been shown for a low
BASDAI [34].
Of note, four patients remained in the study all seven
years despite showing a relatively high disease activity
score. All these patients wished to continue treatment
with etanercept and in these patients a clear reduction of
their CRP values occurred which, interestingly, were also
even lower than the CRP values of the other 12 patients,
with the exception of year 5. More long-term studies
would be necessary to investigate the importance of a con-
stantly low CRP value on the long-term outcome of AS.
The long-term safety outcome in the present study was
very good. Overall, >60% of the initially included patients
remained on continuous treatment with etanercept over
seven years. This is the highest rate of drug survival over
such a long-term treatment period reported in the litera-
ture so far for any patients treated with anti-TNF. Even
in studies with AS patients, who overall reported higher
rates of drug survival as compared to studies with rheu-
matoid arthritis [35-37], drop-out rates were reported to
be as high as 50% of the initially included patients [34].
However, as recently reported [34], a substantial propor-
tion of patients may discontinue their participation in a
clinical study in the long-term also due to other reasons
than adverse events. We did not see any specific signs of
safety issues in the patients who discontinued etanercept
treatment in our study. However, it is important to men-
tion that we did see newly developed Crohn´s disease in
one of our patients as well as the reactivation of Crohn´s
disease in another patient under etanercept treatment.
The potential of reactivation of Crohn´s disease under
treatment with etanercept has already been described in
an extensive meta-analysis some years ago [38]. Never-
theless, at present, there is no evidence that etanercept
leads more often to flares of Crohn´s disease or any other
inflammatory bowel diseases as compared to patients
with AS who are not being treated with anti-TNF [38].
Another important safety aspect that needs to be men-
tioned is the recurrent uveitis rates in a substantial num-
ber (44%) of patients, as well as the fact that the majority
of those patients developed uveitis after treatment initia-
tion. Nevertheless, the majority of them (71%) showed no
more than 2 episodes during the seven years of the study,
while, on the other hand, one patient reported 11 epi-
sodes during the entire study period. In a recent analysis
of several etanercept trials in AS, the uveitis rates were
lower in these patients before treatment with etanercept
and were lower compared to patients treated with a pla-
cebo [39].
Conclusions
In conclusion, in this long-term follow-up study with AS
patients treated continuously over seven years, etanercept
showed a sustained efficacy and good safety profile, con-
firming the usage of TNF-blockers in patients with active
disease. Drug survival rates were high in this small cohort.
The ASDAS is reliably assessing the long-term outcome of
AS patients treated with anti-TNF. Its use as a predictive
tool for long-term treatment outcome needs to be shown
in larger studies.
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